Welcome to our dedicated page for Venus Concept news (Ticker: VERO), a resource for investors and traders seeking the latest updates and insights on Venus Concept stock.
Venus Concept Inc. (NASDAQ: VERO) is a medical aesthetic technology company whose news flow reflects both its product developments and its capital and strategic actions. The company describes itself as a global medical aesthetic technology leader with a portfolio of minimally invasive and non-invasive systems for body, face, skin and hair restoration applications. Its updates often highlight device platforms such as Venus Versa, Venus Legacy, Venus Bliss, Venus Viva, Venus Epileve, AI.ME and, more recently, the next-generation Venus NOVA platform.
On this news page, readers can follow VERO news related to quarterly financial results, regulatory milestones, financing transactions and strategic portfolio moves. Recent press releases have covered second and third quarter financial results, including revenue by region and product category, gross profit trends, operating expenses and operating loss. Management commentary in these releases discusses the performance of energy-based device revenues, the impact of macroeconomic conditions on capital equipment sales, and the company’s efforts in cost containment and operational streamlining.
Venus Concept’s news also includes regulatory and product announcements, such as FDA 510(k) clearance for Venus NOVA, a multi-application platform for non-invasive body and skin treatments that integrates Adaptive EMS, proprietary (MP)² technology and Advanced VariPulse. In addition, the company reports on capital structure and financing events, including registered direct offerings of common stock, private placements of warrants, bridge loan drawdowns and debt-to-equity exchanges of subordinated convertible notes into Series Y Preferred Stock.
Another recurring theme in VERO news is the company’s strategic initiatives, notably the definitive agreement to sell its Venus Hair business, which includes NeoGraft and the ARTAS iX Robotic Hair Restoration system, to MHG Co. Ltd. Investors and observers can use this page to monitor how these developments evolve over time, from transaction announcements and court-related updates to subsequent financial disclosures.
Venus Concept (NASDAQ: VERO) will release its second quarter fiscal year 2022 financial results on August 12, 2022, before market opening. Management will hold a conference call at 8:00 a.m. ET on the same day to discuss the results, which will include a Q&A session. Participants can join via phone or a live webcast available on the investor relations website. Venus Concept is a leader in medical aesthetic technology, offering a subscription-based sales model and operates in over 60 countries with a diverse product portfolio.
Venus Concept (NASDAQ: VERO) reported Q1 2022 financial results revealing total revenue of $26.4 million, a 17% increase year-over-year. U.S. revenue surged 25% to $13.1 million, driven by strong sales in their Body Franchise. However, the company faced a GAAP net loss of $8.6 million, a reduction from $9.4 million last year. Adjusted EBITDA loss widened by 17% to $5.9 million. Looking forward, the company anticipates total revenue growth of 20% to 23% for 2022, equating to $126 million to $130 million.
Venus Concept (NASDAQ: VERO) has received FDA 510(k) clearance for its Venus BlissMAX device, expanding its use to include non-invasive lipolysis for the back and thighs, along with a 50% increase in RF energy output to 150 watts. This advancement enhances treatment efficiency and versatility, offering laser fat reduction, cellulite reduction, and muscle conditioning in one platform. The commercial launch of BlissMAX aims to provide physicians with a cost-effective solution that requires little downtime, potentially increasing revenue for customers.
Venus Concept (NASDAQ: VERO) has initiated a U.S. Investigational Device Exemption (IDE) clinical study for its Aime™ robotic platform, aimed at treating moderate to severe facial wrinkles. The study, involving up to 70 participants aged 22 to 75, will assess the safety and efficacy of Aime in a multicenter trial across four centers. Initial patient treatment has been successfully completed. The Aime technology may enhance treatment delivery and visualization, potentially positioning Venus Concept as a leader in robotic aesthetic procedures.
Venus Concept (NASDAQ: VERO) has announced that it will release its first quarter fiscal year 2022 financial results on May 12, 2022, after market close. A conference call to discuss these results will take place at 5:00 p.m. Eastern Time, including a question and answer session for participants. Interested parties can join the call via phone or through a live webcast on the company's investor relations website.
This release marks an important date for investors looking to understand the company's performance in the competitive medical aesthetic technology market.
Venus Concept (NASDAQ: VERO) announced the submission of a 510(k) premarket notification to the FDA for its Aime™ robotic technology, aimed at tissue excision and skin resurfacing. This is a significant milestone as it marks the company's efforts to secure FDA clearance for innovative non-surgical treatments. CEO Domenic Serafino expressed optimism about Aime's potential to revolutionize medical aesthetics and aims for a U.S. commercial launch by Q4 2022. Venus Concept is recognized for its advanced aesthetic and hair restoration solutions across over 60 countries.
Venus Concept (NASDAQ: VERO) reported Q4 2021 revenue of $32.6 million, marking a 26% increase year-over-year. U.S. revenue surged 42% to $16.5 million, driven by strong system adoption, particularly for Venus Bliss and hair restoration products. Gross margin improved to 70%, up 5.3% percentage points. The operating loss decreased by 60% to $4.1 million, while net loss reduced 70% to $4.3 million. For 2022, management projects revenue growth of 20% to 23%, targeting $126 million to $130 million in total revenue.
Venus Concept, a global leader in medical aesthetic technology and listed on NASDAQ under VERO, announced its participation in the Maxim Virtual Growth Conference from March 28th to 30th, 2022. Management will deliver an on-demand presentation starting March 28th. Additionally, they will engage in a panel discussion titled 'Aesthetic Device Industry Panel' on March 28th at 1:00 PM Eastern time. Interested participants can register for the event and access the presentations via Maxim's M-Vest website.
Venus Concept, a leader in medical aesthetic technology, announced its participation in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference. The management will engage in a virtual fireside chat on February 16, 2022, at 11:00 a.m. ET. The webcast will be accessible to BTIG clients attending the event. Venus Concept offers a diverse product range, including aesthetic devices and hair restoration technologies, and operates in over 60 countries. Notable backers include EW Healthcare Partners and HealthQuest Capital.
Venus Concept (NASDAQ: VERO) announced its fourth quarter and fiscal year 2022 financial results will be released on March 28, 2022, before market opening. A conference call is scheduled for the same day at 8:00 a.m. ET to discuss the results, followed by a Q&A session. Participants can join via phone or through a live webcast on the investor relations website. Venus Concept specializes in minimally invasive and non-invasive medical aesthetic technologies, operating in over 60 countries with a subscription-based sales model.